Early time-to-relapse as a predictor of survival in mature T-cell/NK-cell lymphomas: Results from the PETAL consortium

Key Points

To explore the impact of time-to-relapse on overall survival in mature T-cell lymphomas and assess second-line therapy effects.
Global retrospective cohort study of nMTCL cohorts from PETAL and GELL.
Included patients with PTCL-NOS, AITL/TFHL, or ALCL who relapsed or started second-line therapy.
Used Kaplan-Meier and Cox proportional hazards methods for survival analysis.
TTR12 associated with significantly worse overall survival (aHR 2.14; p<0.001).
Patients receiving novel agents as second-line therapy improved survival compared to chemotherapy (aHR 0.60; p=0.038).
TTR12 predicted poorer survival across multiple analyses and patient subgroups.

We only have this paper's title and publication details.

Retrospective cohort study links early time-to-relapse to poorer survival in mature T-cell lymphomas, suggesting treatment options.

No takes yet. Share an insight, caveat, or question.

Kendall et al. (2025) studied this question.

View at Publisher

Ask AI

Bookmark

Share